Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202604105 A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014) New Drug Phase Ⅲ
N202604115 A randomized, open-label (unblinding), crossover bioequivalence study to compare two dydrogesterone F.C. tablets in healthy female subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202604120 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEWMDD-1) New Drug Phase Ⅲ
N202604145 A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat New Drug Phase Ⅱ
N202604152 Energy-Efficient Edge AI for Pervasive Health Monitoring: Self- Calibrating PPG Blood Pressure and Posture Analysis for Orthostatic Hypotension and Fall Prevention New Medical Device NA
N202605011 A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) New Drug Phase Ⅲ
N202605012 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations New Drug Phase Ⅰ
N202605040 Development and Validation of a Novel Generative AI-driven Digital Therapeutics Platform to Implement Personalized Cognitive Stimulation for Alzheimer's Disease: Year 2-4 Continuation Study New Medical Device NA
N202605041 A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) New Drug Phase Ⅲ
N202605042 A preliminary relative bioavailability study to compare 2.5 mg riociguat F.C. tablet with 7.5 mg riociguat CR tablet in healthy male subjects under fasted state. New Drug NA
1 2 43 44 45 46 47 48 49 50 51 52 / 52

TOP